Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Vaccinex, Inc. (VCNX)

0.4879   0.047 (10.53%) 11-28 16:00
Open: 0.5 Pre. Close: 0.4414
High: 0.53 Low: 0.447
Volume: 193,542 Market Cap: 21(M)

Technical analysis

as of: 2022-11-28 4:44:00 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 0.65     One year: 0.75
Support: Support1: 0.41    Support2: 0.34
Resistance: Resistance1: 0.55    Resistance2: 0.64
Pivot: 0.53
Moving Average: MA(5): 0.46     MA(20): 0.54
MA(100): 0.77     MA(250): 1.07
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 17.4     %D(3): 8.7
RSI: RSI(14): 41.7
52-week: High: 2.27  Low: 0.41
Average Vol(K): 3-Month: 69 (K)  10-Days: 55 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VCNX ] has closed above bottom band by 29.1%. Bollinger Bands are 1.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.53 - 0.53 0.53 - 0.54
Low: 0.44 - 0.44 0.44 - 0.45
Close: 0.48 - 0.49 0.49 - 0.49

Company Description

Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed a proprietary drug discovery platform, ActivMAb that it is leveraging through strategic collaborations, by exploiting its unique capability to select antibodies against multi-pass membrane receptors. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Headline News

Mon, 28 Nov 2022
Should You Accumulate Vaccinex Inc (VCNX) Stock Monday? - InvestorsObserver

Mon, 28 Nov 2022
Vaccinex raises $3.8M in direct stock offering (NASDAQ:VCNX) - Seeking Alpha

Mon, 14 Nov 2022
Vaccinex Earnings, Revenue Beat in Q3 By -

Mon, 14 Nov 2022
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update - Yahoo Finance

Mon, 14 Nov 2022
Vaccinex GAAP EPS of -$0.11, revenue of $0.05M (NASDAQ:VCNX) - Seeking Alpha

Thu, 10 Nov 2022
2022-11-10 | NDAQ:VCNX | Press Release | Vaccinex Inc. - Stockhouse

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 43 (M)
% Held by Insiders 2.597e+007 (%)
% Held by Institutions 12 (%)
Shares Short 86 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.01e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -40
Return on Assets (ttm) 610
Return on Equity (ttm) -106.7
Qtrly Rev. Growth 50000
Gross Profit (p.s.) 0
Sales Per Share -99.72
EBITDA (p.s.) -1.54857e+007
Qtrly Earnings Growth -0.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -20 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 264280
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.